Global Leader in Innovation & Clinical Research for Lung Disease

Our team at UH Rainbow Babies & Children’s Hospital includes some of the nation’s leading pulmonary physicians. We are driven by the desire to improve outcomes for children and young adults with lung-related diseases. By dedicating expertise and resources to medical research and clinical trials, we have been able to pioneer several groundbreaking treatment options for children in our care - and around the world.

Access to More Clinical Trials and Advanced Treatment Options

As an academic medical center, our patients have access to innovative treatment options before they are commercially available. We actively participate in translational research, meaning we translate research findings into everyday practice. Through this approach, our lab-based scientists collaborate with clinicians at the point of care. We can bring scientific discoveries to our patients quickly, for added benefits.

Lung-related diseases can be very complex, and a tailored approach is crucial. We review each patient’s specific case and determine which clinical trials might be an appropriate fit.

World’s First Stem Cell Trial for People with Cystic Fibrosis

Cystic fibrosis (CF) is a genetic disease that limits the ability to breathe over time. UH Rainbow Babies & Children’s is a leader in the mission to find lifesaving therapies for children and adults with this devastating diagnosis.

Our board-certified pulmonary specialists participate in ongoing clinical trials and research, including the world’s first stem cell clinical trial for people with CF. Participants receive an infusion of an adult stem cell, which could hold the key to reduced inflammation and infection among CF patients. The trial will offer cystic fibrosis specialists a first look at how stem cell treatment could improve quality of life for people with a cystic fibrosis diagnosis.

The CF stem cell trial at UH Rainbow Babies & Children’s Hospital is funded by the Cystic Fibrosis Foundation. It is part of an extensive pediatric pulmonology research portfolio that includes eight active studies in asthma, 29 active studies in CF, one active study in pulmonary hypertension and two active studies in primary ciliary dyskinesia.

Advancing Standards of Care Through Collaboration

To advance treatment options for children with pulmonary diseases, UH Rainbow Babies & Children’s collaborates with many nationally-recognized institutions, including Case Western Reserve University School of Medicine.

Together, we’ve been able to achieve scientific discoveries that are now a mainstay of treatment. This collaborative approach to research has also led to new personalized, small-molecule therapies for severe asthma and CF. By testing combinations of drugs, our physicians and researchers have been able to better understand which drugs will likely work best for individual patients.

UH Rainbow Babies & Children’s is also part of an asthma research network called the PrecISE Network, which stands for Precision Interventions for Severe and/or Exacerbation Prone Asthma. Funded by the National Institutes of Health, our pediatric asthma specialists are seeking innovative therapies to help patients when standard therapies are unsuccessful. Our team is researching biological medications or biologics – which will be given by injection to patients with severe asthma. These promising discoveries give hope to our patients – and those that benefit from our research.

The collaboration between basic science, clinical research and patient care continues to yield positive outcomes and long-term rewards for pediatric patients with pulmonary diagnoses.